These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling. Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092 [TBL] [Abstract][Full Text] [Related]
23. Monitoring of influenza virus hemagglutinin in process samples using weak affinity ligands and surface plasmon resonance. Mandenius CF; Wang R; Aldén A; Bergström G; Thébault S; Lutsch C; Ohlson S Anal Chim Acta; 2008 Aug; 623(1):66-75. PubMed ID: 18611459 [TBL] [Abstract][Full Text] [Related]
25. Recombinant influenza A viruses harboring optimized dicistronic NA segment with an extended native 5' terminal sequence: induction of heterospecific B and T cell responses in mice. Vieira Machado A; Naffakh N; Gerbaud S; van der Werf S; Escriou N Virology; 2006 Feb; 345(1):73-87. PubMed ID: 16271378 [TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and evaluation of biomimetic affinity ligands for elastases. Filippusson H; Erlendsson LS; Lowe CR J Mol Recognit; 2000; 13(6):370-81. PubMed ID: 11114070 [TBL] [Abstract][Full Text] [Related]
27. Influenza recombinant vaccine: matrix protein M1 on the platform of the adenovirus dodecahedron. Naskalska A; Szolajska E; Chaperot L; Angel J; Plumas J; Chroboczek J Vaccine; 2009 Dec; 27(52):7385-93. PubMed ID: 19766576 [TBL] [Abstract][Full Text] [Related]
28. Molecular characterization and phylogenetic analysis of H1N1 and H3N2 human influenza A viruses among infants and children in Thailand. Chutinimitkul S; Chieochansin T; Payungporn S; Samransamruajkit R; Hiranras T; Theamboonlers A; Poovorawan Y Virus Res; 2008 Mar; 132(1-2):122-31. PubMed ID: 18160168 [TBL] [Abstract][Full Text] [Related]
29. [Synthesis and properties of an affinity adsorbent for purifying neuraminidases of varying origins]. Poltorak AN; Martiushin SV; Pasechnik VA Prikl Biokhim Mikrobiol; 1985; 21(3):365-71. PubMed ID: 2864684 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456 [TBL] [Abstract][Full Text] [Related]
32. Identification of critical contact residues in the NC41 epitope of a subtype N9 influenza virus neuraminidase. Nuss JM; Whitaker PB; Air GM Proteins; 1993 Feb; 15(2):121-32. PubMed ID: 7680132 [TBL] [Abstract][Full Text] [Related]
33. A generic system for the expression and purification of soluble and stable influenza neuraminidase. Schmidt PM; Attwood RM; Mohr PG; Barrett SA; McKimm-Breschkin JL PLoS One; 2011 Feb; 6(2):e16284. PubMed ID: 21326879 [TBL] [Abstract][Full Text] [Related]
34. Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006. Bauer K; Richter M; Wutzler P; Schmidtke M Antiviral Res; 2009 Apr; 82(1):34-41. PubMed ID: 19428593 [TBL] [Abstract][Full Text] [Related]
35. Development of new stereodiverse diaminocyclitols as inhibitors of influenza virus neuraminidase. Cui Y; Jiao Z; Gong J; Yu Q; Zheng X; Quan J; Luo M; Yang Z Org Lett; 2010 Jan; 12(1):4-7. PubMed ID: 20000379 [TBL] [Abstract][Full Text] [Related]
36. Expression, purification and characterization of low-glycosylation influenza neuraminidase in α-1,6-mannosyltransferase defective Pichia pastoris. Yang YL; Chang SH; Gong X; Wu J; Liu B Mol Biol Rep; 2012 Feb; 39(2):857-64. PubMed ID: 21567198 [TBL] [Abstract][Full Text] [Related]
37. Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies. Lackenby A; Democratis J; Siqueira MM; Zambon MC Antivir Ther; 2008; 13(6):809-20. PubMed ID: 18839782 [TBL] [Abstract][Full Text] [Related]
38. Characterization of human H1N1 influenza virus variants selected in vitro with zanamivir in the presence of sialic acid-containing molecules. Giannecchini S; Campitelli L; Bandini G; Donatelli I; Azzi A Virus Res; 2007 Nov; 129(2):241-5. PubMed ID: 17765996 [TBL] [Abstract][Full Text] [Related]
39. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956 [TBL] [Abstract][Full Text] [Related]